The serotonin transporter in rhesus monkey brain: comparison of DASB and citalopram binding sites

Nuclear Medicine and Biology

Volumn 33, Issue 4, 2006, Pages 555-563

  Zeng, Zhizhen ^a   Chen, Tsing Bau ^a   Miller, Patricia J ^a   Dean, Dennis ^a   Tang, Yui Sing ^a   Sur, Cyrille ^a   Williams Jr , David L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Autoradiography; Citalopram; DASB; Rhesus monkey; SERT; SSRI

Indexed keywords

CARBON 11; CITALOPRAM H 3; FLUOXETINE; N,N DIMETHYL 2 (2 AMINO 4 CYANOPHENYLTHIO)BENZYLAMINE C 11; N,N DIMETHYL 2 (2 AMINO 4 CYANOPHENYLTHIO)BENZYLAMINE H 3; RADIOLIGAND; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BINDING SITE; BRAIN; BRAIN MEMBRANE; BRAIN SLICE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; DRUG PROTEIN BINDING; FRONTAL CORTEX; IN VITRO STUDY; NONHUMAN; OPTICAL DENSITY; POSITRON EMISSION TOMOGRAPHY; PROTEIN LOCALIZATION; RHESUS MONKEY; TISSUE HOMOGENATE;

ANIMALS; AUTORADIOGRAPHY; BENZYLAMINES; BINDING SITES; BRAIN; CITALOPRAM; MACACA MULATTA; METABOLIC CLEARANCE RATE; PROTEIN BINDING; RADIOPHARMACEUTICALS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TISSUE DISTRIBUTION; TRITIUM;

EID: 33646587965     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2006.02.007     Document Type: Article

References (34)

1. Scheffel U., et al. Development of PET/SPECT ligands for the serotonin transporter. NIDA Res Monogr 138 (1994) 111-130
2. Hesse S., et al. Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders. Neurosci Biobehav Rev 28 6 (2004) 547-563
3. Meyer J.H., et al. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry 61 12 (2004) 1271-1279
4. Lundquist P., et al. Potential of [11C]DASB for measuring endogenous serotonin with PET: binding studies. Nucl Med Biol 32 2 (2005) 129-136
5. Houle S., et al. Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB. Eur J Nucl Med 27 11 (2000) 1719-1722
6. Wilson A.A., et al. Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio)araalkylamines. J Med Chem 43 16 (2000) 3103-3110
7. Wilson A.A., et al. In vitro and in vivo characterisation of [11C]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography. Nucl Med Biol 29 5 (2002) 509-515
8. Hummerich R., et al. DASB - in vitro binding characteristics on human recombinant monoamine transporters with regard to its potential as positron emission tomography (PET) tracer. J Neurochem 90 5 (2004) 1218-1226
9. Li Q., et al. Pharmacological and genetic characterization of two selective serotonin transporter ligands: 2-[2-(dimethylaminomethylphenylthio)]-5-fluoromethylphenylamine (AFM) and 3-amino-4-[2-(dimethylaminomethyl-phenylthio)]benzonitrile (DASB). J Pharmacol Exp Ther 308 2 (2004) 481-486
10. Huang H.D., Narendran R., Sudo Y., Chatterjee R., Bae S.A., Mawlawi O., et al. Comparative evaluation in nonhuman primates of five PET radiotracers for imaging the serotonin transporters: [11C]McN 5652, [11C]ADAM, [11C]DASB, [11C]DAPA, and [11C]AFM. J Cereb Blood Flow Metab 22 11 (2002) 1377-1398
11. Belanger M.J., et al. Biodistribution and radiation dosimetry of [11C]DASB in baboons. Nucl Med Biol 31 8 (2004) 1097-1102
12. Meyer J.H., et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am J Psychiatry 158 11 (2001) 1843-1849
13. Meyer J.H., et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 161 5 (2004) 826-835
14. Frankle W.G., et al. Comparative evaluation of serotonin transporter radioligands 11C-DASB and 11C-McN 5652 in healthy humans. J Nucl Med 45 4 (2004) 682-694
15. Frankle W.G., et al. Serotonin transporter availability in patients with schizophrenia: a positron emission tomography imaging study with [11C]DASB. Biol Psychiatry 57 12 (2005) 1510-1516
16. Chalon S., et al. Pharmacological characterization of N,N-dimethyl-2-(2-amino-4-methylphenyl thio)benzylamine as a ligand of the serotonin transporter with high affinity and selectivity. J Pharmacol Exp Ther 304 1 (2003) 81-87
17. Larsen A.K., et al. Selectivity of (3)H-MADAM binding to 5-hydroxytryptamine transporters in vitro and in vivo in mice; correlation with behavioural effects. Br J Pharmacol 141 6 (2004) 1015-1023
18. Lundberg J., et al. Quantification of 11C-MADAM binding to the serotonin transporter in the human brain. J Nucl Med 46 9 (2005) 1505-1515
19. Halldin C., et al. [(11)C]MADAM, a new serotonin transporter radioligand characterized in the monkey brain by PET. Synapse 58 3 (2005) 173-183
20. D'Amato R.J., et al. Selective labeling of serotonin uptake sites in rat brain by [3H]citalopram contrasted to labeling of multiple sites by [3H]imipramine. J Pharmacol Exp Ther 242 1 (1987) 364-371
21. Dewar K.M., et al. [3H]paroxetine binding and serotonin content of rat and rabbit cortical areas, hippocampus, neostriatum, ventral mesencephalic tegmentum, and midbrain raphe nuclei region. Synapse 9 1 (1991) 14-26
22. Dewar K.M., et al. [3H]paroxetine binding and serotonin content of rat cortical areas, hippocampus, neostriatum, ventral mesencephalic tegmentum, and midbrain raphe nuclei region following p-chlorophenylalanine and p-chloroamphetamine treatment. J Neurochem 58 1 (1992) 250-257
23. Soucy J.P., et al. Validation of the transporter ligand cyanoimipramine as a marker of serotonin innervation density in brain. J Nucl Med 35 11 (1994) 1822-1830
24. Hyttel J., et al. The pharmacological effect of citalopram residues in the (S)-(+)- enantiomer. J Neural Transm Gen Sect 88 2 (1992) 157-160
25. Hogg S., and Sanchez C. The antidepressant effects of citalopram are mediated by the S-(+)- and not the R-(-)-enantiomer. Eur Neuropsychopharmacol 9 Suppl 1 (1999) S213
26. Sanchez C., et al. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl) 174 2 (2004) 163-176
27. Chen F., et al. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 15 2 (2005) 193-198
28. Chen F., et al. Characterization of an allosteric citalopram-binding site at the serotonin transporter. J Neurochem 92 1 (2005) 21-28
29. Plenge P., and Wiborg O. High- and low-affinity binding of S-citalopram to the human serotonin transporter mutated at 20 putatively important amino acid positions. Neurosci Lett 383 3 (2005) 203-208
30. Henry L.K., et al. Tyr-95 and ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants. J Biol Chem 281 4 (2006) 2012-2023
31. Smith H.R., et al. Distribution of [3H]citalopram binding sites in the nonhuman primate brain. Ann NY Acad Sci 877 (1999) 700-702
32. Varnas K., Halldin C., and Hall H. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp 22 3 (2004) 246-260
33. Miller G.M., et al. Cloning of dopamine, norepinephrine and serotonin transporters from monkey brain: relevance to cocaine sensitivity. Brain Res Mol Brain Res 87 1 (2001) 124-143
34. Hume S.P., et al. Evaluation of S-[11C]citalopram as a radioligand for in vivo labelling of 5-hydroxytryptamine uptake sites. Int J Radiat Appl Instrum B Nucl Med Biol 19 8 (1992) 851-855